impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer

Aromatase inhibitors (AIs) have become the standard adjuvant therapy of postmenopausal breast cancer survivors. AIs induce a reduction of bioavailable estrogens by inhibiting aromatase, which would be expected to induce alterations in body composition, more extensive than induced by menopause. The o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2011-01, Vol.125 (2), p.441-446
Hauptverfasser:	van Londen, G. J, Perera, S, Vujevich, K, Rastogi, P, Lembersky, B, Brufsky, A, Vogel, V, Greenspan, S. L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adipose Tissue - physiology Adjuvant treatment Analysis Aromatase inhibitors Aromatase Inhibitors - administration & dosage Aromatase Inhibitors - therapeutic use Biological and medical sciences body composition Body Composition - drug effects Body fat Body Mass Index Bone Density - drug effects Breast cancer breast neoplasms Breast Neoplasms - blood Breast Neoplasms - drug therapy Breast Neoplasms - physiopathology Cancer Cancer research Cancer therapies Clinical Trial Clinical trials Double-Blind Method Estrogen Etidronic Acid - analogs & derivatives Etidronic Acid - therapeutic use Female Gonadal hormones Gonadal Hormones - blood Gynecology. Andrology. Obstetrics Hormones Humans Impact analysis Inhibitor drugs Mammary gland diseases Medical sciences Medicine Medicine & Public Health Menopause Middle Aged Oncology Physiological aspects Placebos Postmenopausal women Postmenopause Risedronate Sodium Sex Hormone-Binding Globulin - analysis Testosterone Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!